Dempze Nancy E Exelixis, Inc. Transaction History
Dempze Nancy E
- $162 Million
- Q3 2024
A detailed history of Dempze Nancy E transactions in Exelixis, Inc. stock. As of the latest transaction made, Dempze Nancy E holds 16,000 shares of EXEL stock, worth $544,480. This represents 0.26% of its overall portfolio holdings.
Number of Shares
16,000Holding current value
$544,480% of portfolio
0.26%Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
502Shares Held
243MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.14 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$997 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$865 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$523 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$389 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...